Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07ESH
|
|||
| Former ID |
DCL000594
|
|||
| Drug Name |
PF-1913539
|
|||
| Synonyms |
Sch-58261; Sch 58261; 160098-96-4; Sch58261; 2-(Furan-2-yl)-7-phenethyl-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; UNII-4309023MAH; CHEMBL17127; 4309023MAH; 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine; 2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; 5-Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine; [3H]SCH 58261; SCH58261
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9] | Discontinued in Phase 3 | [1] | |
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H15N7O
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)CCN2C3=C(C=N2)C4=NC(=NN4C(=N3)N)C5=CC=CO5
|
|||
| InChI |
1S/C18H15N7O/c19-18-22-16-13(11-20-24(16)9-8-12-5-2-1-3-6-12)17-21-15(23-25(17)18)14-7-4-10-26-14/h1-7,10-11H,8-9H2,(H2,19,22)
|
|||
| InChIKey |
UTLPKQYUXOEJIL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 160098-96-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7980583, 10258377, 14900558, 26753254, 33500024, 47510090, 47731275, 50068074, 57395307, 76160696, 85209294, 85286114, 85788185, 90341001, 91746416, 99431535, 103180831, 103978930, 104425548, 121362004, 126671705, 129418187, 134339148, 134340512, 134341517, 135153621, 135651030, 135651205, 135697574, 142362474, 144240144, 144240145, 162023190, 162223707, 163124439, 163565213, 164759434, 170474553, 175612758, 176225385, 179294000, 184538735, 196376772, 198945991, 202558330, 204360450, 215780619, 223454701, 223519245, 223660679
|
|||
| ChEBI ID |
CHEBI:93424
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021875) | |||
| REF 2 | Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia. 2003 Aug;43(2):190-4. | |||
| REF 3 | Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol. 2001 Sep;134(1):68-77. | |||
| REF 4 | Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochem Pharmacol. 1999 Jan 1;57(1):65-75. | |||
| REF 5 | Pfizer. Product Development Pipeline. March 31 2009. | |||
| REF 6 | Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med. 2003 Nov;136(5):474-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.